The Epigenetic Modification of SLC5A8 in Papillary Thyroid Carcinoma and Its Effects on Clinic-Pathological Features
-
Sara Sheikkholeslami
,
Fereidoun Azizi
,
Asghar Ghasemi
,
Abbas Alibakhshi
,
Hossein Parsa
,
Setareh Shivaee
,
Marjan Zarif-Yeganeh
,
Mehdi Hedayati
,
Ladan Teimoori-Toolabi
Abstract
Background: Epigenetic alterations such as DNA methylation are known as the main cause of different types of cancers through inactivation of tumor suppressor genes, especially thyroid cancer. Identification of novel and effective markers are important in diagnosis and prevention of thyroid cancer. In the present study, the expression and methylation of Solute carrier family 5 member 8 (SLC5A8) in Papillary Thyroid Carcinoma (PTC) in comparison to multinodular goiter (MNG) have been studied.
Methods: Overall, 41 patients with PTC and 36 patients affected by MNG were recruited from four hospitals in Tehran and Qazvin, Iran in 2018. Thyroid tissues were obtained during thyroidectomy. RNA and DNA were extracted from thyroid tissues. Quantitative RT-PCR assay was performed for determining the mRNA level of SLC5A8 while Methylation-Sensitive High-Resolution Methylation was applied for assessing the methylation status.
Results: Methylation status of three regions composed of 52 CpG islands in the promoter of SLC5A8 gene was studied by HRM assay. SLC5A8 level in PTC tissues was significantly downregulated in average 0.4 fold in comparison with MNG tissues (P=0.05). The aberrant methylation of SLC5A8 (b) region was remarkably different in PTC and MNG cases. The promoter methylation of SLC5A8 (c) was significantly related to BRAF mutations and vascular invasion in PTC patients.
Conclusion: The aberrant promoter hyper methylation of SLC5A8 was related to aggressive PTC. Therefore, there is some evidence to support the hypothesis that SLC5A8 could be a paly important role in the development of PTC.
2. Safavi A, Azizi F, Jafari R, et al (2016). Thyroid Cancer Epidemiology in Iran: a Time Trend Study. Asian Pac J Cancer Prev, 17(1): 407-12.
3. Zarkesh M, Zadeh-Vakili A, Azizi F, et al (2018). Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes. Mol Diagn Ther, 22(1): 41-56.
4. Hedayati M, Zarif Yeganeh M, Sheikholeslami S, et al (2016). Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer. Crit Rev Clin Lab Sci, 53(4): 217-27.
5. Demokan S, Chuang AY, Pattani KM, et al (2014). Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer. Oncol Rep, 31(2): 1014-20.
6. Rodríguez-Rodero S, Delgado-Álvarez E, Díaz-Naya L, et al (2017). Epigenetic modulators of thyroid cancer. Endocrinol Diabetes Nutr, 64(1): 44-56.
7. Ahmed AA, Essa MEA (2019). Potential of epigenetic events in human thyroid cancer. Cancer Genet, 239: 13-21.
8. Zafon C, Gil J, Pérez-González B, et al (2019). DNA methylation in thyroid cancer. Endocr Relat Cancer, 26(7): R415-R439.
9. Khatami F, Larijani B, Heshmat R, et al (2017). Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer. PLoS One, 12(9): e0184892.
10. Fagerberg L, Hallström BM, Per Oksvold, et al (2014). Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics, 13(2): 397-406.
11. Hernández-Juárez J, Vargas-Sierra O, et al (2019). Sodium-coupled monocarboxylate transporter is a target of epigenetic repression in cervical cancer. Int J Oncol, 54(5): 1613-1624.
12. Park JY, Kim D, Mihi Yang, et al (2013). Gene silencing of SLC5A8 identified by genome-wide methylation profiling in lung cancer. Lung Cancer, 79(3): 198-204.
13. Bhutia YD, Babu E, Ramachandran S, et al (2016). SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. Biochem J, 473(9): 1113-24.
14. Khatami F, Larijani B, Heshmat R, et al (2020). Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF(V600E) mutation as biomarkers for papillary thyroid carcinoma. J Cell Physiol, 235(10):6954-6968.
15. Rismani E, Fazeli MS, Mahmoodzadeh H, et al (2017). Pattern of LRP6 gene expression in tumoral tissues of colorectal cancer. Cancer Biomark, 19(2): 151-159.
16. Li F, He H (2018). Assessing the Accuracy of Diagnostic Tests. Shanghai Arch Psychiatry, 30(3): 207-212.
17. Ganapathy V, Thangaraju M, Gopal E, et al (2008). Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J, 10(1): 193.
18. Mariangela Zane, Marco Agostini, Maria Vittoria Enzo, et al (2013). Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer. Biomed Pharmacother, 67(8): 723-30.
19. Ganapathy V, Gopal E, Miyauchi S, et al (2005). Biological functions of SLC5A8, a candidate tumour suppressor. Biochem Soc Trans, 33(Pt 1): 237-40.
20. Hui Li, Lois Myeroff, Dominic Smiraglia, et al (2003). SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A, 100(14): 8412-7.
21. Schagdarsurengin U, Gimm O, Dralle H, et al (2006). CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid, 16(7): 633-42.
22. Xing, M (2007). Gene methylation in thyroid tumorigenesis. Endocrinology, 148(3): 948-53.
23. Shuiying Hu, Dingxie Liu, Ralph P Tufano, et al (2006). Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer, 119(10): 2322-9.
| Files | ||
| Issue | Vol 51 No 3 (2022) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v51i3.8940 | |
| Keywords | ||
| DNA methylation Gene expression Genes Tumor suppressor Thyroid cancer Papillary | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
